These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26858798)

  • 21. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus.
    Mahling M; Schork A; Nadalin S; Fritsche A; Heyne N; Guthoff M
    Kidney Blood Press Res; 2019; 44(5):984-992. PubMed ID: 31437852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.
    Ichimori S; Shimoda S; Goto R; Matsuo Y; Maeda T; Furukawa N; Kawashima J; Kodama S; Sekigami T; Isami S; Nishida K; Araki E
    J Diabetes Investig; 2012 Mar; 3(2):179-84. PubMed ID: 24843563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study.
    Furukawa S; Miyake T; Miyaoka H; Matsuura B; Hiasa Y
    Diabetes Ther; 2022 May; 13(5):1073-1082. PubMed ID: 35426601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and associated metabolic factors of fatty liver disease in the elderly.
    Wang Z; Xu M; Peng J; Jiang L; Hu Z; Wang H; Zhou S; Zhou R; Hultström M; Lai EY
    Exp Gerontol; 2013 Aug; 48(8):705-9. PubMed ID: 23721951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study.
    Katsuyama H; Sako A; Adachi H; Hamasaki H; Yanai H
    J Clin Med Res; 2015 Jun; 7(6):479-84. PubMed ID: 25883713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
    Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
    Tsimihodimos V; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.
    Gallo S; Calle RA; Terra SG; Pong A; Tarasenko L; Raji A
    Diabetes Ther; 2020 Aug; 11(8):1849-1860. PubMed ID: 32648108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cinnamon supplementation on glucose, lipids levels, glomerular filtration rate, and blood pressure of subjects with type 2 diabetes mellitus.
    Sengsuk C; Sanguanwong S; Tangvarasittichai O; Tangvarasittichai S
    Diabetol Int; 2016 Jun; 7(2):124-132. PubMed ID: 30603255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus.
    Usui M; Tanaka M; Takahashi H
    J Clin Transl Endocrinol; 2020 Sep; 21():100233. PubMed ID: 32904185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.